Our Global Presence
Dr. Reddy’s custom manufacturing operates in India, Mexico and the UK. These facilities have been built and are operated in accordance with the latest cGMP regulatory guidelines. Health and safety compliance is of the highest priority, our dedicated team combined with world-class production facilities and techniques guarantees timely delivery of products to customers throughout the world.
Hyderabad is the corporate center for Dr. Reddy’s CPS and India has outstanding capabilities for API and dosage form manufacturing.
Six commercial production units – All inspected by USFDA
Six Pilot Plant and two kilo labs
Over 2 million liters of reactor capacity
Operations are fully integrated through SAP
7 Dosage facilities
3 Pilot plant
Full range of packaging options: blisters, bottles, pouches, tubes, jars, vials
Technology Development Centers (Hyderabad)
18 State-of-the-art chemistry labs
Pilot plant/Kilo lab spread over 10,000sq.ft
25-250 L reactors (stainless steel and glass-lined)
Wide range of temperature condition capabilities (-80 to 300 °C)
Class 100,000 clean room
3 Analytical labs
Chemical and Hazard Evaluation Laboratory
Our facility located in Cuernavaca, Mexico is US FDA inspected and consists of seven manufacturing bays. The facility is extremely well constructed and maintained with excellent systems and processes. The site manufactures a range of active pharmaceutical ingredients including naproxen & naproxen sodium, steroids derivatives and a range of intermediates innovator companies based in North America and Europe.
Installed production capacity: 3350 tons
7 Reactor bays with reactor volume ranging from 100 L to 20 kL
1000 L and 3000 L cryogenic reactors capable of minus 110 ºC
Facility audited multiple times by US FDA
Approx. 400 employees including 25 post-graduates and 100 graduates (chemists, engineers, accountants)
CPS has excellent R&D capabilities in Cambridge and manufacturing facilities located in Mirfield.
2 dedicated API manufacturing facilities
GMP pilot plant and kilo lab
2 pilot plants for pharmaceutical intermediates
Commercial facility for intermediate manufacture
Site is US FDA and MHRA inspected